Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 2000, p. 3012-3016, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
In Vitro Efficacy of Nikkomycin Z against the Human
Isolate of the Microsporidian Species Encephalitozoon
hellem
Elisa
Bigliardi,1
Anna Maria
Bernuzzi,2
Silvia
Corona,3
Simonetta
Gatti,2
Massimo
Scaglia,4,* and
Luciano
Sacchi3
Department of Evolutionary Biology,
University of Siena,1 Parasitology
Laboratory, Virology Service, IRCCS San
Matteo,2 Department of Animal Biology,
University of Pavia,3 and Infectious
Diseases Research Laboratories, University-IRCCS San
Matteo,4 Pavia, Italy
Received 14 January 2000/Returned for modification 10 April
2000/Accepted 3 August 2000
 |
ABSTRACT |
Since 1985 microsporidia have been recognized as a cause of
emerging infections in humans, mainly in immunocompromised human immunodeficiency virus-positive subjects. As chitin is a basic component of the microsporidian infective stage, the spore, we evaluated in vitro the susceptibility of a human-derived strain of
Encephalitozoon hellem to nikkomycin Z, a
peptide-nucleoside antibiotic known as a competitive inhibitor of
chitin synthase enzymes. Transmission electron microscopy showed that
this drug, at 25 µg/ml, reduced the number of parasitic foci by about
35% ± standard deviation after 7 days of culture (P < 0.0001) and induced cell damage of both mature and immature spores
and also other sporogonic and merogonic stages. In particular, an
irregular outline of the cell shape and an abnormally condensed
cytoplasm in meronts and sporonts were documented. Also, the polar
tubule and the polaroplast membranes appeared disarrayed in the
sporoblast stage. The spore wall showed an enlarged endospore and
delaminated exospore. Mature spores had a complete cytoplasmic
disorganization and a swollen and delaminated cell wall. No
ultrastructural cell damage was observed in uninfected control cultures
treated with the drug.
 |
INTRODUCTION |
Microsporidia are widespread,
obligate intracellular parasites of most vertebrates and invertebrates.
In addition to their causing infections in animals (19),
there is great interest in studying these microorganisms because some
genera and species have been recognized as a cause of opportunistic
infections in immunocompromised humans, chiefly human immunodeficiency
virus-positive subjects (9). Although albendazole, a
benzimidazole derivative, has been found to be effective in vitro and
in a series of patients infected by Encephalitozoon spp. to
date there are no other drugs that are proved consistently
efficacious against microsporidia infecting humans.
The microsporidian spore is the stage of the parasite that contains
chitin in the cell wall (2, 3, 4). Chitin provides high
resistance to the environment and confers structural rigidity to the
infective stage. Chitin is a carbohydrate polymer not present in
mammalian cells, and chitin synthesis inhibition should be a target for
microsporidian-specific therapy.
Nikkomycin Z (NIK-Z) is a peptide-nucleoside antibiotic that was
recovered as a potent competitive inhibitor of chitin synthase enzymes
of fungi and insects and has structural similarity to UDP-N-acetylglucosamine (6, 7). In particular
NIK- Z has been found to be effective in vitro and in vivo against
some extracellular and intracellular fungal pathogens (5, 12, 13,
16). Moreover, this drug is well tolerated and easily degradable
(11, 12) and therefore also might be considered as a
potential candidate for therapeutic use against microsporidia. We
present the results of a preliminary in vitro study on the
sensitivity of NIK-Z on a human isolate of Encephalitozoon
hellem.
 |
MATERIALS AND METHODS |
Culture system.
The study was performed on a E. hellem isolate (PV-5-95) from a subject with asymptomatic
microsporidiosis (18). The strain was cocultured in
25-cm2 Corning flasks at 37°C on monolayers of a fetal
bovine lung fibroblast (FBLF) cell line which was grown in Eagle
minimal essential medium (E-MEM) and supplemented with 10%
heat-inactivated fetal calf serum, 1% penicillin-streptomycin
solution, and 1% glutamine. The medium was replaced twice a week.
Microsporidian spores were periodically harvested from the supernatant
by centrifugation at 3,000 × g and stored at +4°C,
to provide the spore concentration for the study protocol. About
107 spores were collected from each flask after 4 weeks of
infection. Cell monolayers were infected with 100 µl of a suspension
of 109 spores/ml.
The control cultures (FBLF plus E. hellem) were
microscopically inspected in order to draw the growth curve. The mean
counts of parasitic foci/centimeter squared were performed daily for 1 week postinfection by inverted microscope (objective, 16×; Leitz Diavert, Wetzlar, Germany). The mean number of parasitic foci was
defined by counting 30 microscopic fields at a magnification of ×160.
At the 7th day postinfection, the cultures were fixed for transmission
electron microscopy study.
Drug solution.
A 0.1 M stock solution of NIK-Z
(Sigma-Aldrich, Milan, Italy) was prepared in E-MEM and diluted in
culture medium to give the working solution of 25 µg/ml. The
inhibitory effects of NIK-Z were previously studied in vitro within the
concentration range from 0.002 to 202 µM on Candida
albicans (5) and on Geotrichum candidum and
at concentrations ranging from 1 to 100 µM on Mucor plumbeus (21).
Evaluation of drug effect.
The drug solution was added to
the culture medium of both infected and control flasks at the 16th h
and was replaced every 24 h. A count of cells showing parasitic
foci per centimeter squared was performed microscopically, and the mean
number of infected cells was obtained from six experiments.
To evaluate the infectivity rate of the
E. hellem spores
obtained from the NIK-Z-treated cultures, spores were harvested every
day and counted. In addition, these spores were adjusted to a
concentration of 10
9 spores/ml and inoculated onto fresh
FBLF to determine if a new
infection would take
place.
Microscopical observations were performed every day until 10 days
postinfection. Each pharmacological test was repeated six
times, and
each mean point was determined from six
replicates.
Statistical analysis.
Repeated-measure analysis of variance
(ANOVA) was used to test for statistically significant changes in
number of foci over time and between groups; difference between two
groups at one specific time was evaluated by the Mann-Whitney U test.
We used Bonferroni's correction (17) to adjust the observed
significance level to the number of multiple comparisons. All
tests were two tailed. Analyses were performed with the statistics
package SPSSPC (1998 release).
 |
RESULTS |
The treatment with NIK-Z (25 µg/ml) significantly inhibited the
in vitro rate of infection in FBLF monolayers parasitized with E. hellem. The presence of parasitic foci was observed from 8 h
to 7 days posttreatment. The percentage of treated infected cells never
rose above 30%, whereas the number of infected cells in the control
cultures increased to about 70% (Fig.
1). ANOVA by repeated measures showed
that effects of both treatment and time were significant (treatment,
F1,10 = 1,269.84 [P = 0.000]; time,
F8,80 = 928.73 [P = 0.000]). There
were significant interactions between treatment and time
(F8,80 = 89.45 [P = 0.000]). For
all evaluated time frames, except the comparisons at 16 and 24 h, the differences between the two groups were significant
(P < 0.0055 for the differences to be significant
after Bonferroni's correction) (Table
1).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of E. hellem grown in FBLF cells,
after treatment with NIK-Z (number of spores added, 100 µl of a
suspension of 109 spores/ml; drug concentration, 25 µg/ml). Each point represents the mean number ± standard error
of parasitic foci in 30 microscopic fields (magnification, ×160) in
six experiments. Bars indicate standard error. These data cross index
to those reported in Table 1.
|
|
No ultrastructural damages were seen in the host cells (FBLF) treated
with NIK-Z during the experimental time schedule (188 h) (Table
2).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Reduction of the infective potentiality of residual
E. hellem spores collected in cultures previously
treated for 188 h with NIK-Z
|
|
The transmission electron microscopy study showed cell damage in both
merogonic and sporogonic stages. In particular, we documented an
irregular outline of the cell shape and an abnormally condensed cytoplasm in meronts and sporonts (Fig.
2A),
whereas the polar tubule and the
polaroplast membranes appeared disarrayed in the sporoblast stage (Fig.
2B). The nucleus, the polar coils, and the polaroplast membranes of the
treated spores were also disarrayed, and the cytoplasm appeared
vacuolated and misshapen. The spore wall was abnormally shaped, with an
enlarged endospore and delaminated exospore (Fig. 2C). Mature spores
were too severely damaged and distorted, with a complete cytoplasmic
disorganization and a swollen and delaminated cell wall (Fig. 2D). In
addition to these ultrastructurally abnormal features, the parasites
were often seen surrounded by host cell cytoplasm, as a consequence of
the disrupted limiting membrane of the parasitophorous vacuole.

View larger version (147K):
[in this window]
[in a new window]
|
FIG. 2.
Electron micrographs of E. hellem in FBLF
cells treated with NIK-Z (25 µg/ml) for 48 h. (A) Meronts (m)
and sporonts (s) showing irregular outline of cell shape: membrane
bundles (arrow) and abnormally condensed cytoplasm were observed in the
meront and an empty nucleus (n) in the sporont. (Bar = 0.6 µm.) (B)
Sporoblast showing irregular cell outline, disarrayed polar coils
(arrows), and the polaroplast membranes (arrowhead). (Bar = 0.43 µm.)
(C) "Young" spore showing nucleus (n), polar coils (arrows), and
disarrayed polaroplast membranes (*). The cytoplasm appears
vacuolated and misshapen. The exospore is delaminated. (Bar = 0.25 µm.) (D) Mature spores are severely damaged and greatly distorted.
Note the complete disruption of the cytoplasmic organization. The
endospore (*) appears extremely enlarged, and the exospore appears
delaminated (arrows) and swollen (double arrows). (Bar = 0.37.)
|
|
On the contrary, no damage was seen in control cultures treated with
NIK-Z but not infected with microsporidia.
Finally, spores collected in the supernatant of drug-treated cultures
after 1 week of incubation also demonstrated a dramatic decrease in
infectivity: fewer parasitic foci were detected after 7 days
in monolayers infected with treated parasites than in the control
parasites (Fig. 3). ANOVA by repeated
measures showed that effects of both treatment and time were
significant (treatment, F1,10 = 3415.84 [P = 0.000]; time, F5,50 = 138.3 [P = 0.000]). In addition there were significant
interactions between treatment and time (F5,50 = 105.3 [P = 0.000]). In all the time intervals considered,
the two groups were statistically different (P < 0.0083 for the differences to be significant after Bonferroni's
correction) (Table 2).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 3.
Reinfection of FBLF cells with E. hellem
spores previously treated with NIK-Z (number of spores added, 100 µl
of a suspension of 109 spores/ml). Each point represents
the mean number ± standard error of parasitic foci in 30 microscopic fields (magnification, ×160) in six experiments. Bars
indicate standard error. These data cross-index to those reported in
Table 2.
|
|
 |
DISCUSSION |
The working hypothesis of the research, confirmed by our
preliminary data, was that the exposure to inhibitors of chitin
synthase would affect the chitin component of the microsporidian cell
wall and, if chitin indeed has a role in sporogenesis, that this would affect the spore viability and infectivity.
Studies on the molecular phylogeny of the microsporidia demonstrated
that these microorganisms display a large evolutionary distance from most eukaryotes and relegate them closer to the fungi (23). One of the mean features that strengthens the
relationship between microsporidia and fungi is the presence of chitin
and trehalose (2, 4, 15, 22).
In this report we first demonstrated the effect of NIK-Z as a
competitive inhibitor of chitin synthase on morphogenesis of various
stages of an E. hellem microsporidian strain. In fact, in
monolayers treated with NIK-Z at dose of 25 µg/ml, for 48 h of
incubation, we observed that a low percentage of spores was able to
infect new FBLF cultures but at an infectivity rate lower than
that observed in cultures inoculated with nontreated spores.
Moreover, on the basis of our study, we demonstrated NIK-Z is
not directly toxic to the host cell monolayers. Our data agree with the results reported by others on fungal pathogens treated with
the same drug. The inhibitory effect was related to several factors,
such as nutrient concentration in the culture medium (21),
the different affinity for the chitinases (5, 10), the
uptake rate and the affinity for the cellular transport system, and the
peptidase of the infected cells (8).
Unlike several fungal species, microsporidia are obligate intracellular
pathogens. Therefore, the effective concentration of the NIK-Z in these
protozoa was influenced also by the drug transport across the
plasma membrane and by the peptide transport system of the
infected cells. The drug effectiveness might be negatively
affected by the peptidases of the host cell fibroblasts.
Nevertheless, our results indicate that NIK-Z was unable to induce
complete damage of all microsporidia within host cells, so that a
residual number of spores escaped drug effect, even if their
infectivity was partially inhibited. In fact, parasitic foci in FBLF
cells infected with drug-treated spores were observed only after
several days of incubation, and their percentage was significantly
lower than those of controls.
In conclusion, our preliminary results seem to indicate that NIK-Z
could be a candidate drug for the treatment of some microsporidial infections, such as encephalitozoonosis. However, a more extensive study of the drug kinetics and of other strains of the same and other
related species (Encephalitozoon cuniculi, Encephalitozoon intestinalis) is required. Our results also indicate the
need to test this drug on these protozoa in combination with other chemotherapeutic agents, namely, azole derivatives, on the basis of recent successfully performed studies against some chitinous fungi
(1, 14, 20).
 |
ACKNOWLEDGMENTS |
This work was partially supported by the 2nd National AIDS
Project (AIDS-related opportunistic infections and TBC), grant 50B.35,
and MURST 1998-2000 from the Italian Ministry of Health and of
Scientific Research, Rome, Italy.
We thank C. Tinelli, Biometric Unit, IRCCS Policlinico San Matteo,
Pavia, Italy, and P. Galeotti, Department of Animal Biology, University
of Pavia, for the statistical analysis of the study results.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Clinical Parasitology, Infectious Diseases Research Laboratories,
University-IRCCS Policlinico San Matteo, 27100 Pavia, Italy. Phone:
(39) 382- 502.698. Fax: (39) 382-423320. E-mail:
mscaglia{at}smatteo.pv.it.
 |
REFERENCES |
| 1.
|
Andriole, V. T.
1999.
Current and future antifungal therapy: new targets for antifungal agents.
J. Antimicrob. Chemother.
44:151-162[Abstract/Free Full Text].
|
| 2.
|
Bigliardi, E.,
M. G. Selmi,
P. Lupetti,
S. Corona,
S. Gatti,
M. Scaglia, and L. Sacchi.
1996.
Microsporidian spore wall. Ultrastructural findings on Encephalitozoon hellem exospore.
J. Eukaryot. Microbiol.
43:181-186[Medline].
|
| 3.
|
Bigliardi, E.,
S. Gatti, and L. Sacchi.
1997.
Ultrastructure of microsporidian spore wall: the Encephalitozoon cuniculi exospore.
Ital. J. Zool.
64:1-5.
|
| 4.
|
Canning, E. U., and W. S. Hollister.
1991.
In vitro and in vivo investigations of human microsporidia.
J. Protozool.
38:631-635[Medline].
|
| 5.
|
Chapman, T.,
O. Kinsman, and J. Houston.
1992.
Chitin biosynthesis in Candida albicans grown in vitro and in vivo and its inhibition by nikkomycin Z.
Antimicrob. Agents Chemother.
36:1909-1914[Abstract/Free Full Text].
|
| 6.
|
Cohen, E.
1987.
Chitin biochemistry: synthesis and inhibition.
Annu. Rev. Entomol.
32:71-93[CrossRef].
|
| 7.
|
Debono, M., and R. S. Gordee.
1994.
Antibiotics that inhibit fungal cell wall development.
Annu. Rev. Microbiol.
48:471-497[CrossRef][Medline].
|
| 8.
|
Decker, H.,
H. Zahner,
H. Heitsch,
W. A. Konig, and H. P. Fiedler.
1991.
Structure-activity relationships of the nikkomycins.
J. Gen. Microbiol.
137:1805-1813[Abstract/Free Full Text].
|
| 9.
|
Franzen, C., and A. Muller.
1999.
Molecular techniques for detection, species differentiation, and phylogenetic analysis of microsporidia.
Clin. Microbiol. Rev.
12:243-285[Abstract/Free Full Text].
|
| 10.
|
Gaughran, J. P.,
M. H. Lai,
D. R. Kirsch, and S. J. Silverman.
1994.
Nikkomycin Z is a specific inhibitor of Saccharomyces cerevisiae chitin synthase isozyme Chs3 in vivo.
J. Bacteriol.
176:5857-5860[Abstract/Free Full Text].
|
| 11.
|
Graybill, J. R.,
L. K. Najvar,
R. Bocanegra,
R. F. Hector, and M. F. Luther.
1998.
Efficacy of nikkomycin Z in the treatment of murine histoplasmosis.
Antimicrob. Agents Chemother.
42:2371-2374[Abstract/Free Full Text].
|
| 12.
|
Hector, R. F.,
B. L. Zimmer, and D. Pappagianis.
1990.
Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis.
Antimicrob. Agents Chemother.
34:587-593[Abstract/Free Full Text].
|
| 13.
|
Hector, R. F.
1993.
Compounds active against cell walls of medically important fungi.
Clin. Microbiol. Rev.
6:1-21[Abstract/Free Full Text].
|
| 14.
|
Hector, R. F., and K. Schaller.
1992.
Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo.
Antimicrob. Agents Chemother.
36:1284-1289[Abstract/Free Full Text].
|
| 15.
|
Keeling, P. J., and W. F. Doolittle.
1997.
Evidence that eukaryotic triosephosphate isomerase is of alpha-proteobacterial origin.
Proc. Natl. Acad. Sci. USA
94:1270-1275[Abstract/Free Full Text].
|
| 16.
|
Payne, J. V.,
K. J. Barrett-Bee, and D. A. Shallow.
1991.
Peptide substrates rapidly modulate expression of dipeptide and oligopeptide permeases in Candida albicans.
FEMS Microbiol. Lett.
79:15-20[CrossRef].
|
| 17.
|
Rice, W. R.
1989.
Analyzing table of statistical tests.
Evolution
43:223-225[CrossRef].
|
| 18.
|
Scaglia, M.,
S. Gatti,
L. Sacchi,
S. Corona,
G. Chichino,
A. M. Bernuzzi,
G. Barbarini,
G. P. Croppo,
A. Da Silva,
N. J. Pieniazek, and G. S. Visvesvara.
1998.
Asymptomatic respiratory tract microsporidiosis due to Encephalitozoon hellem in three patients with AIDS.
Clin. Infect. Dis.
26:174-176[Medline].
|
| 19.
|
Shadduck, J. A.,
R. Storts, and L. G. Adams.
1996.
Selected examples of emerging and reemerging infectious diseases in animals.
ASM News
62:586-588.
|
| 20.
|
Tariq, V. N.,
E. M. Scott, and N. E. McCain.
1995.
Use of decimal assay for additivity to demonstrate synergy in pair combination of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro.
Antimicrob. Agents Chemother.
12:2615-2619.
|
| 21.
|
Tariq, V. N., and P. L. Devlin.
1996.
Sensitivity of fungi to Nikkomycin Z.
Fung. Gen. Biol.
20:4-11.
|
| 22.
|
Vavra, J.
1976.
Structure of the microsporidia, p. 1-85.
In
L. A. Bulla, Jr., and T. C. Cheng (ed.), Comparative pathology. Plenum Press, New York, N.Y.
|
| 23.
|
Weiss, L. M., and C. R. Vossbrinck.
1999.
Molecular biology, molecular phylogeny, and molecular diagnostic approaches to the microsporidia, p. 129-171.
In
M. Wittner (ed.), The microsporidia and microsporidiosis. American Society for Microbiology, Washington, D.C.
|
Antimicrobial Agents and Chemotherapy, November 2000, p. 3012-3016, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mathis, A., Weber, R., Deplazes, P.
(2005). Zoonotic Potential of the Microsporidia. Clin. Microbiol. Rev.
18: 423-445
[Abstract]
[Full Text]